* A similar preparation of identical characteristics, Protease I (" Astra 1652"), has also been
developed by AB Astra, Sweden, in closecollaboration with Connaugrht Medical Research …

The properties of CA-7, a fibrinolytic agent derived from Aspergillus Oryzae, 1, 2 and its use
in systemic thrombolytic therapy in the dog were previously reported. 3-5 There it was shown …

RESULTS An example illustrating the application of this method to initial evaluation of a
potential thrombolytic agent is summarized in table 1. Sixteen mongrel dogs of either sex …

The lysis of occluding arterial thrombi in dogs with intravenous injections of CA-7 (fibrinolytic
enzyme from Aspergillus oryzae) is described. The treatments were conducted over a 3-day …

Protease resistance, a term applied to the inhibitory effect of all circulating inhibitors of CA-7
(fibrinolytic enzyme from Aspergillus oryzae), was determined in 95 dogs. The frequency …

Case 1.. Mrs. S., aged 34, was undergoing re¬ peated hemodialysis for chronic renal failure
due to chronic pyelonephritis. A standard curved Scribner arteriovenous shunt was being …

CONCLUSIONS Toxicity from intravenous injections of CA-7 was shown to be directly re-
lated to the intensity of induced proteolytic activity. To obtain levels of the enzyme that will be …

In human plasma treated with protease I, there was no demonstrable activation of
plasminogen to plasmin. Such a plasma would, however, release more plasmin when …

1. Protease I was found to have potent fibrinolytic activity in concentrations which exceeded
the blood inhibitory capacity when tested on fibrin plates and artificial thrombi. 2. Plasma …

The fungal protease was administered intravenously in repeated doses to cats. The effect on
clotting time, fibrinogen level, fibrinolytic and activator activity, and serum inhibitor activity of …